Senhance is made by Asensus Surgical, based in Durham, North Carolina, USA, founded in 2006.

Where is Senhance deployed?

No verified deployments of Senhance are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.

What is Senhance's maturity stage?

Senhance is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.

Robot model

Senhance

Name: Senhance
Brand: Asensus Surgical

Asensus Surgical, formerly TransEnterix and based in Durham, North Carolina, was a public company on the NYSE American as ASXC that made the Senhance multi-port laparoscopic robotic system, FDA-cleared via 510(k) in October 2017 with subsequent instrument and indication clearances, making Senhance a genuinely cleared if relatively low-volume commercial product. The headline current-state fact is that Karl Storz acquired the company, closing on August 22, 2024 at $0.35 per share for about $95 million, a roughly 67 percent premium, with the stock ceasing to trade on the NYSE American at close, leaving Asensus a private Karl Storz subsidiary; this is the canonical example of a large medtech company absorbing a struggling robotics startup for a fraction of its historic enterprise value. The registry records Senhance at commercial maturity with an active lifecycle, since it remains a cleared product line continuing under Karl Storz, while the company status is recorded as acquired. The company's next-generation LUNA system, unveiled in February 2023 with claimed real-time clinical intelligence and cloud machine learning, was not FDA-submitted, not cleared, and not for sale as of the August 2024 close, so LUNA is recorded at research maturity, with a 2025 FDA target that is unverified as met and a current status under private ownership that is not publicly traceable. On AI substance the cleared digital-surgery features are machine-vision and digital-laparoscopy assists that are real but incremental rather than autonomy, and the Performance-Guided Surgery framing was oversold relative to what is cleared.

Senhance is a surgical robot built by Asensus Surgical.

Track Senhance

Machine-readable surfaces

Markdown mirror: /models/asensus-senhance.md
JSON-LD: embedded in this page’s head
REST API: /v1/models/abadf566-b528-4b44-be3e-418ca078e920
Revision history: /models/asensus-senhance/history
Data documentation: /data
Query this programmatically: Deploy MCP

Form factor: surgical
Maturity stage: commercial
Lifecycle: active
Deployments: 0
ID: abadf566-b528-4b44-be3e-418ca078e920

Deploy Watch

Track Senhance on Deploy.

We notify you when pricing, deployment status, or regulatory state changes against primary-source evidence, not when the maker issues claims.

Specs

notes: [{"label":"Verified","value":"Asensus Surgical (formerly TransEnterix; Durham NC; was NYSE American: ASXC) made the Senhance laparoscopic robot, FDA-cleared via 510(k) in Oct 2017 with subsequent clearances/indication expansions. Senhance is a genuinely cleared, commercial (if low-volume) product."},{"label":"Current status: ACQUIRED by Karl Storz (the headline)","value":"Karl Storz acquired 100% of Asensus, closing Aug 22 2024 at $0.35/share (~$95M total, ~67% premium); the stock ceased trading on NYSE American at close (delisted; now a private Karl Storz subsidiary). The canonical big-medtech-acquires-struggling-robotics-startup datapoint: a former public-market name sold for a fraction of its historic enterprise value. maturityStage=commercial (Senhance is cleared + still a product line); company status=acquired; lifecycleState=active (Senhance line continues under Karl Storz)."},{"label":"LUNA = research","value":"The next-gen LUNA (real-time 'clinical intelligence' + cloud ML) was NOT FDA-submitted / NOT cleared / NOT for sale as of the Aug 2024 close. Karl Storz had targeted 2025 FDA - that target is unverified as met. LUNA = research-tier; current status under private-owner Karl Storz is not publicly traceable (cap-flag)."},{"label":"AI-substance + claimed-not-verified","value":"Cleared 'digital surgery' substance = machine-vision/digital-laparoscopy assists (real but incremental, not autonomy); 'Performance-Guided Surgery' framing oversold vs what's cleared. NOT verified: LUNA FDA submission/clearance ever occurring; current Senhance installed-unit count (Karl Storz private); whether Senhance is actively commercialized vs wound down under Karl Storz."}]
products: Senhance: FDA-cleared multi-port laparoscopic robotic system (initial 510(k) Oct 2017 as TransEnterix; later 3mm instruments, ultrasonic, indication expansions, machine-vision clearance). LUNA: next-gen system (unveiled Feb 2023) with claimed real-time clinical intelligence + cloud ML; NOT FDA-submitted/cleared, NOT for sale.
formFactor: surgical (multi-port laparoscopic teleoperated robotic system with machine-vision/digital-laparoscopy assists)

Manufacturer-attributed media (1)

Manufacturer-supplied media at the model level. Not tied to an independently verified named-site deployment. Verification posture is product-showcase from the maker, distinct from the deployment-verified evidence in the section above.

PRIMARY SOURCE

Courtesy of Asensus Surgical

Asensus Surgical footage of its Senhance digital-laparoscopy system in a simulation and training environment (not a live clinical case). A surgeon-teleoperated system, not autonomous. FDA 510(k)-cleared (2017) for control of laparoscopic and thoracoscopic instruments; Asensus was acquired by Karl Storz in 2024.

Components (1)

Senhance Instrument Armactuatorsafety-critical(primary safety)
Instrument arm
- actuator failure · critical: FDA recall after reports of unintended/uncontrolled arm movement; device correction.

Components carry componentClass + safetyCritical flag. ModelComponent rows carry safety_role (primary_safety / backup_safety / monitoring / non_safety) + optional supplier identity.

Regulatory filings (2)

fda_recallfda recall · us_fdarecalled2023-09-15
Applicant: Asensus Surgical
K171120fda 510k · us_fdacleared2017-04-14
Applicant: Asensus Surgical

Incidents affecting Senhance (1)

Asensus Senhance Class I recall: software malfunction caused uncontrolled arm motion after disengaging teleop2023-09-15 · Recall

Includes incidents linked directly to this model or to deployments of it. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.

Sources (4)

Common questions

What is Senhance?: Asensus Surgical, formerly TransEnterix and based in Durham, North Carolina, was a public company on the NYSE American as ASXC that made the Senhance multi-port laparoscopic robotic system, FDA-cleared via 510(k) in October 2017 with subsequent instrument and indication clearances, making Senhance a genuinely cleared if relatively low-volume commercial product. The headline current-state fact is that Karl Storz acquired the company, closing on August 22, 2024 at $0.35 per share for about $95 million, a roughly 67 percent premium, with the stock ceasing to trade on the NYSE American at close, leaving Asensus a private Karl Storz subsidiary; this is the canonical example of a large medtech company absorbing a struggling robotics startup for a fraction of its historic enterprise value. The registry records Senhance at commercial maturity with an active lifecycle, since it remains a cleared product line continuing under Karl Storz, while the company status is recorded as acquired. The company's next-generation LUNA system, unveiled in February 2023 with claimed real-time clinical intelligence and cloud machine learning, was not FDA-submitted, not cleared, and not for sale as of the August 2024 close, so LUNA is recorded at research maturity, with a 2025 FDA target that is unverified as met and a current status under private ownership that is not publicly traceable. On AI substance the cleared digital-surgery features are machine-vision and digital-laparoscopy assists that are real but incremental rather than autonomy, and the Performance-Guided Surgery framing was oversold relative to what is cleared.
Who makes Senhance?: Senhance is made by Asensus Surgical, based in Durham, North Carolina, USA, founded in 2006.
Where is Senhance deployed?: No verified deployments of Senhance are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.
What is Senhance's maturity stage?: Senhance is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.

Methodology: Verified · 4 sources (1 primary) · last reviewed 2026-06-03

Verification posture

Verified

High confidence

Review state

Stable

Last reviewed 2026-06-03

Maturity + lifecycle

Maturity stage: commercial

Lifecycle: active

Architectural position

Cohort: surgical

Sources by quality tier

2: unclassified; Unclassified source
1: primary-company-ir; Company IR disclosure
1: secondary-trade-publication; Trade publication

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.